Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$135.41 USD
-1.25 (-0.91%)
Updated May 31, 2024 04:00 PM ET
After-Market: $135.49 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 81 - 100 ( 307 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
4Q21 Pre-Announcement; Ingrezza Falling Short But FY22 Guidance Still To Come
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Weekly Neurology Prescription Sales Tracker - Week Ending 12/24/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Weekly Neurology Prescription Sales Tracker -- Week Ending 12/10/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Valbenazine Phase 3 KINECT-HD Study Positive-Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
KINECTing For a Win in HD - Phase 3 KINECT-HD Study Meets Endpoint
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Weekly Neurology Prescription Sales Tracker -- Week Ending 11/12/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Adaptation Key for Ingrezza, as HD Data Expected in December; Reit Buy and $140 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Weekly Neurology Prescription Sales Tracker - Week Ending 10/15/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Biotechnology-Weekly Neurology Prescription Sales Tracker
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
3Q21 Commercial Biotech Preview: Will We See Tricks or Treats in 3Q21 Earnings?
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Weekly Neurology Prescription Sales Tracker -- Week Ending 9/24/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Weekly Neurology Prescription Sales Tracker - Week Ending 9/17/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Weekly Neurology Prescription Sales Tracker -- Week Ending 8/20/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L